Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/5438
Study of adherence to Recombinant Growth Hormone treatment of children with a GH deficiency: contributions to treatment control and economic impact
Study of adherence to Recombinant Growth Hormone treatment of children with a GH deficiency: contributions to treatment control and economic impact. Madrid: AETS - Instituto de Salud Carlos III; 2013.
Public Health Technology Assessment Report
The treatment for children with growth hormone deficiency has significantly developed since its first uses from human cadavers (1958), until the arrival of recombinant human growth hormone (1985). This biotechnological advance has allowed an expansion in its uses due to a greater availability, as well as a greater biological safety of this hormone and significant refinements regarding dosage and administration frequency, achieving significant results in the final growth of these children. However, the existence of non- responder phenotypes, as well as the more common lack of therapeutic compliance, can pose severe limitations regarding effectiveness, with the corresponding economic impact for Health Systems, which may be mitigated by innovations in administration devices.
Table of contents
LIST OF ABBREVIATIONS ABSTRACT AND KEY WORDS INAHTA STRUCTURED ABSTRACT BACKGROUND ASSESSMENT OF NORMAL GROWTH GROWTH PHYSIOLOGY GROWTH FACTORS PREDICTION OF ADULT SIZE CONCEPT OF SHORT STATURE CLASSIFICATION OF SHORT STATURE GROWTH HORMONE DEFICIENCY (GHD) Epidemiology of growth hormone deficiency: incidence and prevalence Physiology of growth hormone Aetiology of GH deficiency Clinical expression of growth hormone deficiency Growth hormone deficiency diagnosis Growth hormone deficiency treatment Adherence or compliance problems OBJECTIVES AND HYPOTHESIS OBJETIVES HYPOTHESIS Justification METHODS LITERATURE REVIEW ECONOMIC MODEL RESULTS TYPES OF DEVICES FOR ADMINISTERING GROWTH HORMONE: FACTORS WHICH AFFECT NON-ADHERENCE TO TREATMENT STUDIES THAT TRY TO MEASURE TREATMENT COMPLIANCE WITH GROWTH HORMONE RESULTS OBTAINED IN GROWTH AFTER GROWTH HORMONE THERAPY DISCUSSION CONCLUSIONS BIBLIOGRAPHY ANNEXES ANNEX A. FIGURES ANNEX B. GRAPHS ANNEX C. IMAGES ANNEX D. TABLES